Chronic Insomnia Tied to Higher Risk of Dementia, Heart Disease and Other Major Illnesses

A long-term analysis of older adults has found that chronic insomnia is associated with a substantially higher risk of cognitive impairment and dementia, and researchers and health experts say the consequences of persistent sleep disruption extend across cardiovascular, metabolic and immune systems.

The research, which drew on data from the Mayo Clinic Study of Aging and was published in the journal Neurology, reported that people with chronic insomnia were about 40 percent more likely to develop mild cognitive impairment or dementia than those without chronic sleep problems. The study also found evidence of accelerated brain aging among affected participants, estimating a roughly three- to four-year advance in biological brain age compared with well-sleeping peers.

Researchers linked the cognitive findings to biological markers tied to Alzheimer’s disease, noting greater accumulation of proteins such as amyloid-beta and tau in individuals with prolonged insomnia. The study also examined genetic risk, reporting that the effect of insomnia on cognitive decline was pronounced among many participants but appeared less distinct in carriers of the APOE4 gene, a well-established genetic risk factor for Alzheimer’s; among APOE4 carriers, the genetic risk remained dominant.

Public health analyses estimate that between a third of Americans and as many as 70 million people experience insomnia symptoms, defined by difficulty falling asleep, trouble staying asleep, waking too early or being unable to return to sleep. Investigators and clinicians describe chronic insomnia as a potentially modifiable risk factor that may act both as an early warning sign and as a contributor to later cognitive impairment.

Beyond neurology, the physiological disruption tied to chronic insufficiency of sleep has been shown to affect multiple organ systems. Sleep plays a role in nightly reductions of blood pressure and heart rate that give the cardiovascular system time to rest. When sleep is shortened or fragmented, the normal nocturnal dip in blood pressure may not occur, leaving the heart and blood vessels under sustained daytime pressure levels. Over time, that nonstop stress can contribute to the development of hypertension, a leading risk factor for heart attack and stroke.

Physiologic stress during prolonged wakefulness also increases production of cortisol, a stress hormone, and can promote chronic, low-grade inflammation through elevated inflammatory cytokines. Those changes are implicated in damage to the inner lining of blood vessels, accelerating atherosclerosis — the buildup of plaque inside arteries — and raising the risk of coronary artery disease and other cardiovascular conditions. Current U.S. health statistics estimate that about 121.5 million adults, nearly half the adult population, have some form of heart disease, and roughly 115 million adults have high blood pressure.

Sleep disruption additionally affects metabolic regulation. Short or poor-quality sleep alters hormones that control appetite, increasing levels of ghrelin, which stimulates hunger, and decreasing leptin, which signals satiety. The combined hormonal shift, along with changes in neural reward pathways that enhance the appeal of calorie-dense foods, can lead to increased caloric intake and weight gain. These mechanisms are associated with the rise in obesity rates seen over recent decades; about 40 percent of American adults are classified as having obesity.

Insufficient sleep also undermines glucose regulation and insulin sensitivity. Studies linking sleep loss to impaired insulin action describe a cycle in which sleep deprivation increases inflammation and weight gain, both of which worsen insulin resistance and heighten the risk of developing type 2 diabetes. The U.S. Centers for Disease Control and Prevention estimated that in 2021 about 38.4 million Americans had diabetes, with the vast majority — 90 to 95 percent — having type 2.

The immune system is likewise affected by persistent sleeplessness. Sleep is a period when the body produces and coordinates immune proteins, including cytokines, and supports the generation and function of cells such as T-cells and other white blood cells. Chronic sleep loss has been associated with reduced production and efficacy of these immune components, a blunted antibody response to vaccination and longer recovery times from infections.

Clinicians say the biological picture painted by research — a combination of hormonal imbalance, sustained inflammation, impaired clearance of neural waste products and metabolic dysregulation — helps explain why chronic insomnia correlates with elevated risks across an array of common, serious conditions. The Mayo Clinic Study of Aging findings add to a growing body of evidence linking sleep quality and duration to long-term health outcomes.

Researchers and public health officials note that while observational studies cannot conclusively prove that insomnia causes these outcomes, the consistency of associations across physiological pathways and clinical endpoints supports considering sleep health in prevention strategies. Identifying and treating chronic insomnia remains an area of clinical focus, and experts emphasize the importance of recognizing sleep problems as a component of comprehensive care for older adults and for populations at risk of cardiovascular, metabolic and cognitive decline.

The new analysis underscores the potential population-level impact of improving sleep health, given the high prevalence of sleep disorders and the broad range of diseases associated with chronic sleep disruption. Further research, including intervention trials, is needed to determine whether treating insomnia can reduce the incidence of dementia, heart disease and other chronic conditions linked to long-term sleep loss.